Final agenda Joint EFSPI/BBS Meeting: Precision & Innovative Medicine and Health Technology Assessment

Date: Monday, 28th June 2021, 15:00-17:30 CEST
Webinar: dial-in details will be communicated to registered participants

Please register until the 24th June via the following form; after registration, in due time, participants will receive a calendar invite with the dial-in details.

The webinar is free of charge.


Link to recording

Fred Sorenson, Xcenda, Switzerland Welcome and Introduction

Dan O’Connor, MHRA, UK The UK’s Innovative Licensing and Access Pathway (ILAP) for medicines – A joint MHRA, NICE & SMC initiative

Karen Facey, University of Edinburgh, UK IMPACT HTA – Recommendations for Developing Rare Disease Treatments

Paul Cislo, Jinma Ren and Joseph C. Cappelleri, Pfizer, USA Adjusting Global Survival to Make Results More Relevant and Generalizable to Local Markets

Marc Buyse, IDDI and University of Hasselt, Belgium Net benefit and correlation between benefit and harms

Mark Belger and Marie-Ange Paget, Eli Lilly UK & France Closing the efficacy to effectiveness gap: Generalizing from RCTs to real world populations

Kirsten Herrmann, Exact Sciences, Germany Assessments and reimbursement of gene expression signature tests in Europe

Janneke Boersma, Roche, Netherlands Bridging the gap between Regulatory & HTA approval for Precision Medicine therapies: a case study from the Netherlands

Tay Salimullah, Novartis Gene Therapies, Switzerland & USA Acceptance and Uptake of Cell and Gene Therapies: Lessons Learned and Future Focus (an interactive Q&A that can be viewed on the recording)

Sorry, the comment form is closed at this time.